Chao Zhao,1,* Yan Chen,2,* Weiwei Zhang,2,* Jianrong Zhang,2 Yulian Xu,2 Wenjie Li,2 Sunxiao Chen,3 Anmei Deng2 1Department of Laboratory Diagnostic, the 89th Hospital, Weifang, Shandong, People's Republic of China; 2Department of Laboratory Diagnostic, Changhai Hospital, Second Military Medical University, Shanghai, People's Republic of China; 3Changzheng Hospital, Second Military Medical University, Shanghai, People's Republic of China*These authors contributed equally to this workAim: The aim of the study was to validate the expression of protein tyrosine kinase 6 (PTK6) in nonsmall cell lung cancer (NSCLC), and to evaluate its clinicopathological and prognostic significance.Methods: We first conducted a meta-analysis on the mRNA profiling data sets of NSCLC in the Oncomine database. Then, one of the most significantly upregulated tyrosine kinase targets, PTK6, was further validated by immunohistochemistry in 104 primary NSCLC tumors. Furthermore the association between PTK6 expression, the clinical parameters, and overall survival was further analyzed.Results: Using the Oncomine database, we identified a list of tyrosine kinase genes related to NSCLC, among which PTK6 was the second most overexpressed gene (median rank = 915, P = 2.9 × 10-5). We further confirmed that NSCLC tumors had a higher expression level of PTK6 than normal pulmonary tissues. Moreover, high PTK6 expression correlated positively with shorter overall survival time, but not with other clinicopathological characteristics. In the multivariate Cox regression model, high PTK6 expression was demonstrated to be an independent prognostic factor for NSCLC patients.Conclusion: Our results validated that PTK6 was found to be overexpressed in a proportion of NSCLC samples, and was associated with a poor prognosis, suggesting that this subgroup of NSCLC patients might benefit from PTK6 inhibitors in the future.Keywords: nonsmall cell lung cancer, tyrosine kinase, PTK6, target, prognosis